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NEW IN 2016, UPDATE OF POLISH FORUM  
FOR PREVENTION GUIDELINES ON  
CARDIOVASCULAR RISK ASSESSMENT
1. Pol-SCORE — new tool for global cardiovascular risk 
assessment in the Polish population
2. Comprehensive classification of cardiovascular risk
3. Cardiovascular risk age — new tool for patient education
4. Cardiovascular risk assessment in persons < 40 years of 
age — relative risk charts
5. Risk assessment in qualification for prophylactic phar-
macotherapy
1. CARDIOVASCULAR RISK — DEFINITION 
Cardiovascular disease (CVD) risk means the probability of 
a CVD event of atherosclerotic origin in an individual within 
a specified period of time. The level of risk depends on the 
presence of many individual characteristics and environmen-
tal factors, which are called risk factors. Global risk is an 
estimate of the risk, which considers the exposure to several 
risk factors. Relative risk is the ratio of the absolute risk of 
the occurrence of a specific event in the exposed group to 
the absolute risk in the control group. Absolute risk is the 
probability of the occurrence of a specific event in a studied 
population [1].
2. CARDIOVASCULAR RISK ASSESSMENT  
SHOULD BE PART OF THE MEDICAL VISIT 
Assessment of risk should be based on analysis of medical 
examination, and known CVD risk factors, diseases, and the 
results of available additional tests. Awareness of the patient’s 
www.kardiologiapolska.pl
Polish Forum for Prevention Guidelines on Cardiovascular Risk Assessment: update 2016
85
risk allows appropriate therapeutic decisions and monitoring 
of the effectiveness of treatment [1, 2].
3. SYSTEMATIC CVD RISK ASSESSMENT  
AS A PART OF HIGH-RISK STRATEGY  
IN CVD PREVENTION
Risk assessment is an important part of the so-called high-risk 
strategy, which involves actively searching for people who 
are susceptible to CVD and providing them with appropri-
ate care. Systematic CVD risk assessment is recommended 
in individuals at increased CVD risk, i.e. with family history 
of premature CVD, familial hyperlipidaemia, major CVD risk 
factors (such as smoking, high blood pressure, diabetes mel-
litus, or raised lipid levels), or comorbidities increasing CVD 
risk. It is recommended to repeat CVD risk assessment every 
five years, and more often for individuals with risks close to 
thresholds mandating treatment. Systematic CVD risk assess-
ment may also be considered in men > 40 years of age and 
in women > 50 years of age or post-menopausal without 
known CVD risk factors. 
4. POL-SCORE RISK CHARTS 
In patients aged 40–70 years without CVD or other diseases 
that assign them automatically to high-risk group, the preferred 
tool for global risk assessment are Pol-SCORE charts stand-
ardised for Polish population. They predict the risk of death 
due to a CVD within the next 10 years in persons without 
symptoms of CVD and without diabetes. They integrate the 
following risk factors: age, sex, systolic blood pressure, total 
cholesterol, and smoking [3]. 
5. RISK CATEGORIES
Very high risk — includes patients with at least one of the 
following conditions:
 — documented CVD, clinical (previous acute myocardial 
infarction, acute coronary syndrome, coronary revascu-
larisation and other arterial revascularisation procedures, 
stroke and transient ischaemic attack, aortic aneurysm 
and peripheral artery disease) or unequivocal on imaging 
(plaque on coronary angiography or carotid ultrasound);
 — diabetes mellitus (type 1 or 2) with one or more risk 
factors for CVD (such as smoking, marked hypercholes-
terolaemia, marked hypertension) or with target organ 
damage (such as proteinuria).
 — severe chronic kidney disease (GFR < 30 mL/
min/1.73 m2);
 — estimated risk based on Pol-SCORE charts ≥ 10%. 
High risk — includes patients with at least one of the 
following conditions:
 — markedly elevated single risk factors, in particular total 
cholesterol > 8 mmol/L (> 310 mg/dL), e.g. in familial 
hypercholesterolaemia, or blood pressure ≥ 180/110 
mm Hg;
 — diabetes (type 1 or 2) without CVD risk factors and 
systemic complications (with the exception of young 
people with type 1 diabetes mellitus and without major 
risk factors);
 — moderate chronic kidney disease (GFR 30–59 mL/ 
/min/1.73 m2);
 — estimated risk based on Pol-SCORE charts ≥ 5% and < 10%.
Moderate risk — includes patients with 10-year risk 
of death due to a CVD disease according to Pol-SCORE 
charts ≥ 1% but < 5%.
Low risk — includes patients with 10-year risk of death 
due to a CVD disease according to Pol-SCORE charts < 1% 
[1–3].
6. UNDERESTIMATION OF POL-SCORE CHARTS 
Pol-SCORE charts do not consider several CVD risk fac-
tors. Therefore CVD risk in an individual may be higher 
than estimated, especially in patients with a family history 
of premature CVD, approaching the next age category, with 
sedentary lifestyle or excessive weight, with diabetes, with 
low concentrations of high lipoprotein density cholesterol or 
apolipoprotein A1, increased concentrations of high sensitivity 
C-reactive protein, triglycerides, fibrinogen, homocysteine, 
apolipoprotein B and lipoprotein(a), with familial hypercholes-
terolaemia, with pre-clinical atherosclerosis (e.g. with the pres-
ence of atherosclerotic plaque or increase in intima–media 
thickness of carotid artery in ultrasonographic examination), 
and from lower social classes [1–3].
7. CARDIOVASCULAR RISK IN PATIENTS  
IN AN AGE RANGE (< 40 YEARS OF AGE)  
OUTSIDE THE POL-SCORE CHARTS
In younger people, the low absolute CVD risk may mask sig-
nificant relative risk, which should be modified. In this case 
the use of charts of relative risk is advised (Table 1). They de-
termine how increased total cholesterol concentration, systolic 
blood pressure, and smoking increase the risk of death from 
CVD in relation to people of the same age and sex without 
these risk factors [1–3].
8. CARDIOVASCULAR RISK AGE 
In the education of patients it is useful to use the term “car-
diovascular risk age”. It means the age of a person of the same 
sex with the same risk score but with ideally controlled major, 
modifiable CVD risk factors [1].
9. THERAPEUTIC CONSEQUENCES OF RISK  
ASSESSMENT — PREVENTIVE INTERVENTION 
Recognition of high total CVD risk indicates the need to thor-
oughly analyse its causes and to plan appropriate treatment 
aimed at its reduction, at first by intensive lifestyle modifica-
tion and if not effective by pharmacotherapy. The intensity of 
the recommended risk modification should increase in line 
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with the level of risk. In people who belong to the low-risk or 
moderate-risk group, guidance in order to maintain a low-risk 
or moderate-risk status is recommended [1, 4, 5].
10. PROPHYLACTIC PHARMACOTHERAPY
Implementation of pharmacotherapy to reduce global CVD 
disease risk must take into account the side effects of its 
long-term use and the effect on total and CVD mortality. 
Pharmacotherapy should always be recommended together 
with lifestyle changes. Its implementation should be based on 
data from clinical trials and should aim at reducing CVD risk. 
Global risk ≥ 5% should not be understood as a clear indica-
tion for pharmacotherapy. Such an interpretation is wrong, 
especially in young people [1, 5]. 
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Table 1. Relative risk charts [1]
Non-smokers Smokers
SBP 180 mm Hg 3 3 4 5 6 6 7 8 10 12
SBP 160 mm Hg 2 3 3 4 4 4 5 6 7 8
SBP 140 mm Hg 1 2 2 2 3 3 3 4 5 6
SBP 120 mm Hg 1 1 1 2 2 2 2 3 3 4
4 5 6 7 8 4 5 6 7 8
Total cholesterol [mmol/L]
SBP — systolic blood pressure
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XXIII ŁÓDZKA KONFERENCJA KARDIOLOGICZNA odbędzie się 11 marca 2017 r. w Łodzi, 
w Auli 1000 Centrum Dydaktycznego Uniwersytetu Medycznego (ul. Pomorska 251), 
w godzinach 9.00–16.00. Organizatorem jest Katedra Kardiologii Uniwersytetu Medycznego w Łodzi.
Do udziału zapraszamy lekarzy kardiologów, pielęgniarki, techników i ratowników medycznych, a także 
studentów, doktorantów oraz stażystów. Obowiązuje rejestracja za pomocą formularza elektronicznego 
dostępnego na stronie: www.lkk.umed.pl.
Atrakcyjność tegorocznego programu zwiększa odbywające się równolegle IX Forum  
Kardiologii Obrazowej — konferencja szkoleniowa o statusie szkolenia akredytacyjnego  
Sekcji Echokardiografii Polskiego Towarzystwa Kardiologicznego — szczegóły dostępne pod  
adresem: www.forumkardiologii.umed.pl.
